U.S. pharma big copyright scrapped two experimental weight loss products past year—a as soon as-day-to-day tablet, lotiglipron, as a result of elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, because of strong Unwanted side effects—but CEO Albert Bourla has mentioned the company is determined to “Perform and get” in